SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Lev Radin/Shutterstock
Legal
Regeneron Loses Appeal to Block Amgen’s Eylea Biosimilar
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea.
March 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern halftone collage. Concept of teamwork, problem solving together, business direction, collaborate to win,achieve success. Business creative illustration for web banner, marketing material, business presentation. Vector illustration
GLP-1
Altimmune Jumps On Takeover Rumors After Launching Alcohol Use Disorder Study
The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and alcohol-related liver disease.
March 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Take a chance for keeping advance
Duchenne muscular dystrophy
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys 51 in a patient population amenable to exon 51 skipping.
March 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Lymphocytes and biomedical concept, 3d rendering. 3D illustration.
Cell therapy
5 CAR T Cell Therapies With Autoimmune Readouts in 2025
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune disorders, with several early- to mid-stage readouts expected this year.
March 17, 2025
 · 
9 min read
 · 
Tristan Manalac
Dashed line from pills isolated on white
Pipeline
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
March 14, 2025
 · 
2 min read
 · 
Tristan Manalac
cutting off a row of people into pieces
Layoffs
Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review
Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate luveltamab tazevibulin, which it was studying for ovarian cancer. The biotech will seek licensing opportunities for the asset.
March 14, 2025
 · 
3 min read
 · 
Tristan Manalac
Drug capsules with skull and crossbone on dark stone background.
Business
Pliant Pops Poison Pill as Concentra Threat Looms
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect shareholders against Tang Capital’s growing stake in the company.
March 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative pattern made with a syringe on pastel pink background. Vaccine for Coronavirus infection. Pandemic concept.
Government
FDA Makes Flu Vaccine Recommendations Without Convening Advisors
The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.
March 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Autoimmune disease
Amgen’s Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
With what analysts are calling “strong” data, Amgen plans to file a regulatory submission for Uplizna, currently approved for a rare ocular autoimmune disorder, in myasthenia gravis, in the first half of 2025.
March 13, 2025
 · 
1 min read
 · 
Tristan Manalac
A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance
Manufacturing
J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production
Johnson & Johnson and Legend Biotech hope to hit blockbuster status for Carvykti this year.
March 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two arrows merging into one
Mergers & acquisitions
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
Both Mallinckrodt and Endo have previously declared bankruptcy, linked to opioid-related lawsuits.
March 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Merck building and sign in Silicon Valley
Vaccines
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of its HPV vaccine Gardasil to patients and prescribers.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Weight loss
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
Roche and Zealand plan to study petrelintide as a monotherapy and in combination with CT-388, a dual agonist of the GLP-1 and GIP receptors that Roche picked up in its recent acquisition of Carmot Therapeutics.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
A contemporary artistic collage depicting a hand holding pills, passing them to another hand. The concept of medication and treatment.
Collaboration
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge of late-stage development as well as regulatory and commercialization activities.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More